Evaluating the SUBLOCADE Treatment Exit Strategy

Completed

Conditions studied: Opioid Use Disorder

In brief

The purpose of this study is to observe and assess the successful taper and opioid withdrawal experience after participants stop receiving SUBLOCADE because their healthcare provider determines their disease symptoms have been controlled for at least 9 months and they, together with their healthcare provider, plan to discontinue MOUD.

Key facts

Study ID

NCT05878210

Run by

Indivior Inc.

People needed

12

Starts

2023-11-24

Expected to finish

2025-05-09

Last updated by the study team

2026-01-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must meet all of the following criteria:
• The participant, together with their healthcare provider (the investigator), have previously determined that it is appropriate to stop MOUD treatment, and the participant meets the following criteria:
• Has been treated with at least 12 injections of SUBLOCADE.
• In the opinion of the investigator, has had their OUD symptoms (ie, overdose, illicit/nonmedical use, withdrawal) controlled for at least 9 months.
• In the opinion of the investigator, has had any other substance use disorder (excluding alcohol, nicotine, or cannabis) symptoms controlled for at least 9 months.
• Is willing to complete the Baseline Visit 4 to 8 weeks after the last dose of SUBLOCADE.
• Has signed the ICF and is 18 years of age or older.
• Is not currently using opioids to treat a diagnosis other than OUD.

Where it is running

• Comprehensive Addiction Medicine — Portland, Maine, United States
• Savera Medical Centre — Edmonton, Alberta, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.